Pictet Asset Management
REGN icon

Pictet Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Pictet Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$258M Sell
337,254
-30,616
-8% -$23.4M 0.27% 95
2025
Q4 		$285M Buy
367,870
+44,500
+14% +$30.2M 0.28% 85
2025
Q3 		$182M Buy
323,370
+19,243
+6% +$10.9M 0.18% 136
2025
Q2 		$159M Buy
304,127
+3,171
+1% +$1.77M 0.16% 146
2025
Q1 		$191M Buy
300,956
+86,859
+41% +$59.7M 0.21% 120
2024
Q4 		$153M Sell
214,097
-72,448
-25% -$60.8M 0.16% 152
2024
Q3 		$300M Sell
286,545
-7,219
-2% -$8.03M 0.33% 78
2024
Q2 		$309M Sell
293,764
-110,480
-27% -$107M 0.35% 68
2024
Q1 		$390M Sell
404,244
-30,156
-7% -$28.7M 0.42% 59
2023
Q4 		$382M Buy
434,400
+21,358
+5% +$17.6M 0.42% 58
2023
Q3 		$340M Buy
+413,042
New +$325M 0.42% 61

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Pictet Asset Management's REGN Position: Q1 2026 in Review

Pictet Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 8.3% in Q1 2026, selling an estimated $23.4M and leaving 337,254 shares worth $258M. The position accounts for 0.27% of the portfolio, ranked #95.

Pictet Asset Management first reported a position in REGN in Q3 2023 and has held it in 11 quarters since. The position peaked at $390M in Q1 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Pictet Asset Management held 337,254 shares of Regeneron Pharmaceuticals worth $258M as of Q1 2026.
  • Pictet Asset Management sold 30,616 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $23.4M.
  • Regeneron Pharmaceuticals made up 0.27% of Pictet Asset Management's portfolio in Q1 2026, its #95 holding.
  • Pictet Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Regeneron Pharmaceuticals position peaked at $390M in Q1 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.